Patents Examined by Kevin E. Weddington
  • Alcohol hand sanitizer with improved dermal compatibility and feel
    Patent number: 10588836
    Abstract: Applicants have identified a critical skin benefit package that can be used in liquid alcohol sanitizing compositions that provides lower amounts of skin conditioners in combination with a specific ratio of different emollients that provide improved skin health with chronic repeated use. The package also provides improved skin feel with without a tacky residue upon drying.
    Type: Grant
    Filed: April 12, 2018
    Date of Patent: March 17, 2020
    Assignee: Ecolab USA Inc.
    Inventors: Joseph R. Wegner, Cheryl A. Littau
  • Pharmaceutical compositions of lenvatinib
    Patent number: 10583133
    Abstract: The present invention relates to a pharmaceutical composition comprising lenvatinib mesylate and a stabilizer in an amount of about 10% to about 20% based on the total weight of the composition, wherein the stabilizer is selected from the group consisting of calcium hydroxide and potassium hydroxide; and its process for preparation thereof.
    Type: Grant
    Filed: March 1, 2019
    Date of Patent: March 10, 2020
    Assignee: SHILPA MEDICARE LIMITED
    Inventors: Nijaguni Revansiddayya Rudraswamy Math, Sreenivas Reddy, Ravi Vamsi Peri, Krishnamurthy Toppaladoddi, Shivakumar Pradeep
  • Combination therapy for treatment of restenosis
    Patent number: 10576063
    Abstract: Described herein are methods for distributing a combination of a cell division inhibitor (e.g., temsirolimus or paclitaxel) and dexamethasone to a tissue surrounding a blood vessel for treating vascular diseases. Also disclosed are injectable compositions of a cell division inhibitor (e.g., temsirolimus or paclitaxel) and dexamethasone for delivery into the tissue surrounding a blood vessel for treating vascular diseases.
    Type: Grant
    Filed: May 25, 2018
    Date of Patent: March 3, 2020
    Assignee: Mercator MedSystems, Inc.
    Inventor: Kirk Patrick Seward
  • ST-246 liquid formulations and methods
    Patent number: 10576165
    Abstract: The present invention provides for a novel liquid formulation for solubilizing poorly soluble ST-246 in cyclodextrins and a novel process of making the formulation.
    Type: Grant
    Filed: October 11, 2018
    Date of Patent: March 3, 2020
    Assignee: Siga Technologies Inc.
    Inventors: Shanthakumar R. Tyavanagimatt, Melialani A. C. L. S. Anderson, William Weimers, Gopi Krishna Kasi, N K Peter Samuel, Tove C. Bolken, Dennis E. Hruby
  • Alvocidib prodrugs having increased bioavailability
    Patent number: 10562925
    Abstract: Compounds having the following structure (I): or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, wherein one of R1, R2 or R3 is —P(?O)(OH)2, and the other two of R1, R2 and R3 are each H, are provided. Pharmaceutical compositions comprising the compounds, and methods for use of the compounds for treating diseases associated with overexpression of a cyclin-dependent kinase (CDK) are also provided.
    Type: Grant
    Filed: February 19, 2019
    Date of Patent: February 18, 2020
    Assignee: TOLERO PHARMACEUTICALS, INC.
    Inventors: Adam Siddiqui-Jain, David J. Bearss
  • Solid forms of menaquinols
    Patent number: 10563270
    Abstract: Disclosed are solid forms of menaquinol and processes for obtaining them by chemical or enzymatic reduction of menaquinone. Said solid forms possess high stability to oxidation which allows effective use of menaquinol in the most common formulations wherein vitamin K2 is used.
    Type: Grant
    Filed: March 18, 2016
    Date of Patent: February 18, 2020
    Assignee: Gnosis S.p.A.
    Inventors: Davide Bianchi, Simona Daly, Niccolo Miraglia, Antonella Trentin, Federica Colzani, Francesca Bollini, Cesare Ponzone
  • Inhibition and treatment of bacterial infections by sex-specific GPER targeting
    Patent number: 10561648
    Abstract: The present invention is directed to the use of compounds which are modulators of the G protein-Coupled Estrogen Receptor (GPER) for the inhibition —and/or treatment of Bacterial infections, especially including metMctHin-resistant Staphylococcus aureus (MRSA) infections. Pharmaceutical compositions and methods of treatment of bacterial pathogens, including MRSA are also described.
    Type: Grant
    Filed: January 9, 2017
    Date of Patent: February 18, 2020
    Assignee: STC.UNM
    Inventors: Pamela Hall, Eric R. Prossnitz, Helen J. Hathaway
  • Compositions and methods for topical delivery of prostaglandins to subcutaneous fat
    Patent number: 10556012
    Abstract: Described herein are compositions comprising a prostaglandin FP receptor agonist (PFPRA) compound and a fatty acid ester (e.g., isopropyl myristate), optionally comprising an ointment base such as a hydrocarbon base (e.g., petroleum jelly) and/or an organic alcohol (e.g., propylene glycol), that, when topically applied to the skin, locally delivers a therapeutically effective amount of the PFPRA compound to subcutaneous fat under the skin, and methods of preparation. The therapeutic effect is, for example, reduction of the subcutaneous fat under the skin. Further provided are methods of reducing body fat in a subject comprising topically administering the composition to the subject.
    Type: Grant
    Filed: December 15, 2017
    Date of Patent: February 11, 2020
    Assignee: Topokine Therapeutics, Inc.
    Inventors: Michael S. Singer, Murat V. Kalayoglu
  • 2-amino-N?-benzylideneacetohydrazides and derivatives for the management of CFTR protein mediated diseases
    Patent number: 10555918
    Abstract: This disclosure relates to methods of treating or preventing cystic fibrosis transmembrane conductance regulator (CFTR) mediated diseases such as cystic fibrosis, chronic obstructive pulmonary disease, chronic pancreatitis, chronic bronchitis, asthma, mucus formation, comprising administering an effective amount of a 2-amino-N?-benzylidene-acetohydrazide compound or derivative thereof to a subject in need thereof. In certain embodiments, the 2-amino-N?-benzylidene-acetohydrazide compound is ((E)-N?-(3,5-dibromo-2,4-dihydroxybenzylidene)-2-(m-tolylamino)acetohydrazide; or (E)-N?-(3,5-dibromo-2,4-dihydroxybenzylidene)-2-(p-tolylamino)acetohydrazide.
    Type: Grant
    Filed: May 27, 2016
    Date of Patent: February 11, 2020
    Assignees: Emory University, Bar-Ilan University, Childern's Healthccare of Atlanta, Inc.
    Inventors: Nael McCarty, Guiying Cui, Hanoch Senderowitz, Netaly Khazanov
  • Neoadjuvant therapy for bladder cancer
    Patent number: 10556010
    Abstract: This invention relates to a neoadjuvant therapy for bladder cancer in bladder cancer patients who are scheduled for a cystectomy and methods of carrying out such a neoadjuvant therapy. In particular the invention relates to a composition comprising hexyl 5-ALA ester (HAL) or a pharmaceutically acceptable salt thereof for use in a neoadjuvant therapy for bladder cancer in a bladder cancer patient who is scheduled for a cystectomy, the therapy comprises instilling said composition into the bladder of said patient and exposing the inside of said bladder to light.
    Type: Grant
    Filed: December 19, 2016
    Date of Patent: February 11, 2020
    Assignee: PHOTOCURE ASA
    Inventor: Kjetil Hestdal
  • Methods and compositions for treating diseases and conditions
    Patent number: 10543211
    Abstract: Provided herein include methods and compositions for treating diseases or conditions. In some embodiments provided are methods for treating one or more diseases or conditions selected from the group consisting of hypertension, heart failure, dyspnea, and sleep apnea. In certain embodiments provided are methods that include administering a compound of formula (I) as disclosed herein. In some embodiments provided are methods that include administering a P2X3 and/or a P2X2/3 receptor antagonist.
    Type: Grant
    Filed: December 6, 2018
    Date of Patent: January 28, 2020
    Assignee: Afferent Pharmaceuticals, Inc.
    Inventors: Anthony P. Ford, Julian Paton
  • Salts of tetracyclines
    Patent number: 10543298
    Abstract: A tetracycline salt comprising a tetracycline and an organic acid wherein the organic acid is oxalic acid or maleic acid is provided. The tetracycline is preferably doxycycline, minocycline, sancycline, lymecycline, tetracycline or demeclocycline, and preferred salts include oxycycline maleate, minocycline oxalate, tetracycline oxalate, demeclocycline maleate, demeclocycline oxalate, sancycline maleate, lymecycline maleate, or lymecycline oxalate. A pharmaceutical formulation comprising a tetracycline salt according to the invention is also provided, as is a medical device having coated thereon a salt or pharmaceutical formulation according to the invention. A salt of the invention, or a formulation of the invention are also provided for use as medicaments, particularly for use in the treatment or prevention of an inflammation and/or an infection.
    Type: Grant
    Filed: November 24, 2016
    Date of Patent: January 28, 2020
    Assignee: Hovione Scientia Limited
    Inventors: Luis Sobral, Livia Santana De Arruda, Margarida Figueiredo, Rafael Antunes, Ana Paula Filipe
  • Lipid furan, pyrrole, and thiophene compounds for treatment of cancer, neurological disorders, and fibrotic disorders
    Patent number: 10525031
    Abstract: Compounds, methods, and compositions are provided for the treatment of cancer, neurological disorders, and fibrotic disorders. Specifically, the invention includes administering an effective amount of a compound of Formula I, II, or III, or a pharmaceutically acceptable composition, salt, isotopic analog, prodrug, or combination thereof, to a subject suffering from a cancer, neurological disorder, or fibrotic disorder.
    Type: Grant
    Filed: August 23, 2018
    Date of Patent: January 7, 2020
    Assignee: Avoscience, LLC
    Inventor: Richard Huber
  • Compositions, dosage forms, and co-administration of an opioid agonist compound and an analgesic compound
    Patent number: 10525054
    Abstract: The present invention relates generally to the co-administration of an opioid agonist compound and an analgesic compound. In addition, the invention relates to, among other things, dosage forms for co-administration of an opioid agonist compound and an analgesic compound, methods for administering an opioid agonist compound and an analgesic compound, compositions comprising an opioid agonist compound and an analgesic compound, dosage forms comprising an opioid agonist compound and an analgesic compound, and so on.
    Type: Grant
    Filed: February 9, 2018
    Date of Patent: January 7, 2020
    Assignee: Inheris Biopharma, Inc.
    Inventors: Timothy A. Riley, Juergen W. Pfeiffer, Hema Gursahani
  • Compositions and methods for treatment of inflammation
    Patent number: 10525027
    Abstract: The present invention is directed to novel anti-inflammatory immunomodulators including creatinine or a creatinine salt, for example, creatinine hydrochloride. The present invention is also directed to methods for treating inflammation and inducing an immunomodulatory response. In particular, the anti-inflammatory immunomodulators are useful for treating an inflammatory condition or an autoimmune disease.
    Type: Grant
    Filed: May 15, 2018
    Date of Patent: January 7, 2020
    Assignees: Vireo Systems, Inc., Creighton University
    Inventors: Thomas McDonald, Kristen Drescher
  • Compounds for treatment of cancer
    Patent number: 10525037
    Abstract: The present invention relates to pharmaceutical compositions for treating cancer comprising BRAF inhibitors, (e.g. vemurafenib) and/or MEK inhibitor, (e.g. trametinib, RO5068760), in combination with anti-tubulin compounds of the invention or other known tubulin inhibitors, and using such compositions for treating cancer such as melanoma, drug-resistant cancer, and cancer metastasis.
    Type: Grant
    Filed: July 12, 2018
    Date of Patent: January 7, 2020
    Assignee: UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION
    Inventors: Jin Wang, Jianjun Chen, Duane D. Miller, Wei Li
  • Compositions and methods for treating conditions related to adrenocortical activity and/or excessive steroid production
    Patent number: 10512667
    Abstract: Provided herein are methods for treating subjects having conditions related to adrenocortical activity and/or excessive steroid production. In particular, provided herein are methods for treating subjects having conditions related to adrenocortical activity and/or excessive steroid production through administration of at least one of the following agents: 1) an agent capable of inhibiting cholesterol efflux related to ABCA1 and/or ABCG1; 2) an agent capable of inhibiting MDR1 related cortisol secretion and/or MDR1 P-glycoprotein multiple drug transporter activity; and 3) an agent capable of inhibiting mitochondrial activity.
    Type: Grant
    Filed: June 27, 2018
    Date of Patent: December 24, 2019
    Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Tom K. Kerppola, Veronica E. Burns
  • 3-(phenyl)-N-(4-phenoxybenzyl)-1,2,4-oxadiazole-5-carboxamide compounds for the management of CFTR protein mediated diseases
    Patent number: 10512636
    Abstract: This disclosure relates to methods of treating or preventing cystic fibrosis transmembrane conductance regulator (CFTR) mediated diseases such as cystic fibrosis, chronic obstructive pulmonary disease, chronic pancreatitis, chronic bronchitis, asthma, mucus formation, comprising administering an effective amount of a 3-(phenyl)-N-(4-phenoxybenzyl)-1,2,4-oxa-diazole-5-carboxamide compound, salt, or derivative thereof to a subject in need thereof. In certain embodiments, the 2-amino-N-benzylidene-acetohydrazide compound is 3-(3,5-dibromo-4-hydroxyphenyl)-N-(4-phenoxybenzyl)-1,2,4-oxadiazole-5-carboxamide.
    Type: Grant
    Filed: May 27, 2016
    Date of Patent: December 24, 2019
    Assignees: Emory University, Children's Healthcare of Atlanta, Inc.
    Inventors: Nael McCarty, Guiying Cui
  • Combination therapy of HSP90 inhibitors with platinum-containing agents
    Patent number: 10500193
    Abstract: A pharmaceutical combination comprising a platinum-containing anticancer agent, and an Hsp90 inhibitor according to the following formulae (I) & (Ia), a tautomer, or a pharmaceutically acceptable salt thereof, wherein the variables structural formulae are defined herein. Also provided is a method of treating a proliferative disorder such as cancer in a subject in need thereof, using the pharmaceutical combination described herein.
    Type: Grant
    Filed: March 29, 2018
    Date of Patent: December 10, 2019
    Assignee: Synta Pharmaceuticals Corporation
    Inventor: David Proia
  • Method for treating developmental retinal vascular disorder
    Patent number: 10493044
    Abstract: A method for treating a subject suffering from a developmental retinal vascular disorder by administering to the subject a composition which has a therapeutically effective amount of a dendrobium nobile lindley (DNL).
    Type: Grant
    Filed: May 29, 2018
    Date of Patent: December 3, 2019
    Inventor: Hsiao-Ming Chao